<DOC>
	<DOCNO>NCT01716975</DOCNO>
	<brief_summary>The purpose study determine EVP-6124 ( alpha-7 nAChR agonist ) enhance cognitive ability subject Schizophrenia also take stable antipsychotic therapy .</brief_summary>
	<brief_title>Study EVP-6124 ( Alpha-7 nAChR ) Adjunctive Pro-Cognitive Treatment Schizophrenia Subjects Chronic Stable Atypical Antipsychotic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Age 18 50 year age , inclusive Signed inform consent , indicate subject understands purpose procedure require study , initiation study specific procedure . Subjects unable provide inform consent include study . Resides stable living situation , accord investigator 's judgment , must identify informant consistent throughout study . If possible , informant accompany subject available person rating screening , baseline ( Day 1 ) , final study visit . In person informant rating relevant study visit prefer whenever possible . However , informant available person rating , telephone interview acceptable . The informant must available telephone interview throughout study visit . As long informant visit subject visit within study visit window , necessary occur day . The informant must interact subject least 2 time week . Diagnosis Schizophrenia least 3 year duration . This diagnosis establish utilizing SCIDI , direct clinical assessment , family , informant , confirmation diagnosis clinical source . These may include medical record , confirmation diagnosis treat clinician telephone contact , write confirmation treat clinic . If listed source available , source diagnostic confirmation may also acceptable discussion medical monitor . Treated atypical antipsychotic drug ( approve dosage form ) Clozapine stable dose least 8 week prior screen clinically stable ; subject must remain clinically stable ( opinion principal investigator ) randomization . The use 2 atypical antipsychotic drug permit , long opinion investigator , second medication require control treatmentresistant intractable psychotic symptom . No subject wash antipsychotic therapy become eligible study . Schizophrenia clinical symptom burden severity define follow : Brief Psychiatric Rating Scale ( BPRS ) Conceptual Disorganization item score ≤ 4 ; BPRS Hallucinatory Behavior item score ≤ 5 , Unusual Thought Content item score ≤ 5 . Either Hallucinatory Behavior Unusual Thought Content , , may score 6 ( &gt; 6 ) . SimpsonAngus Scale ( SAS ) total score ≤ 6 Calgary Depression Scale Schizophrenia ( CDSS ) total score ≤ 10 General health status acceptable participation 26week clinical study Fertile , sexually active subject ( men woman ) must use effective method contraception study Fluency ( oral write ) language standardized test administer The ability refrain use tobacco nicotinecontaining product least 30 minute cognitive test Hospitalization within 12 week screen screening period , change antipsychotic medication dose within 8 week screen screening period . Participation another therapeutic ( medication administration ) clinical study within past 2 month . Psychiatric hospitalization incarceration due breakthrough symptom acute exacerbation period 3 month screen . Subjects recent `` social '' hospitalization incarceration may enter screen consultation medical monitor Likelihood , opinion investigator , either subject informant unable complete 26week study Treatment prohibit antipsychotic drug , and/or treatment 2 permit antipsychotic drug . Treatment firstgeneration antipsychotic drug ( typical antipsychotic ) prohibit unless administer low dose discussion medical monitor Current treatment anticholinergic agent Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) criteria meet alcohol abuse within past 3 month substance abuse ( nicotine ) within last 6 month screen Significant suicide risk define 1 ) suicidal ideation endorse item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) within past year ; 2 ) suicidal behavior detect CSSRS past 2 year , 3 ) psychiatric interview examination Stroke within 6 month screen , history brain tumor , subdural hematoma , clinically significant neurological condition , head trauma loss consciousness within 12 month screen Monoamine oxidase inhibitor antidepressant tricyclic medication use antidepressant dos exclude . Other antidepressant medication allow subject treat stable dose least 3 month screen Immunosuppressants , mood stabilizer , chronic use sedative hypnotic drug , chronic intake clinically significant dos opioid contain analgesic current methadone treatment judgment investigator may permit depend circumstance Use Central Nervous System ( CNS ) stimulant Nicotine therapy ( include patch ) , varenicline ( Chantix ) , similar therapeutic agent within last six month screen Use benzodiazepine medication allow subject change medication dose least 3 month . For subject prescribe benzodiazepine , shortacting benzodiazepine use whenever possible . Use longeracting benzodiazepine may acceptable prior authorization obtain medical monitor . When possible , benzodiazepine administer within 3 hour cognitive test . The use one sedativehypnotic medication allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cognition Impairment</keyword>
	<keyword>Alpha-7 nAChR</keyword>
</DOC>